Every 424B that BiomX Inc. (PHGE) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow PHGE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PHGE filings page.
BiomX Inc. (PHGE) may offer and sell shares of its common stock having an aggregate offering price of up to $9,145,000 from time to time through H.C. Wainwright & Co. under an at-the-market Sales Agreement, subject to General Instruction I.B.6 of Form S-3. This amount is in addition to approximately $3,708,127 of common stock already sold under the same program and related prior prospectus supplements. The company reports a public float of $38,560,317.12, based on 24,718,152 non-affiliate shares at $1.56 per share as of May 28, 2026. Its common stock trades on NYSE American under the symbol PHGE, with a last reported sale price of $0.1948 per share on July 27, 2026.
BiomX Inc. is registering the resale of up to 7,163,000 shares of common stock for selling stockholders, including 2,223,000 already issued shares, 4,615,000 warrant shares and up to 325,000 shares issuable upon conversion of a $3,000,000 unsecured note at a $12.00 conversion price.
The company will not receive proceeds from stockholder resales, only potential cash from warrant exercises, which it plans to use for general corporate purposes. If all warrants are exercised and the note is fully converted, these shares would represent about 52.3% of then-outstanding stock and roughly 109.5% of shares outstanding before the April 2026 Water IO transaction, meaning substantial dilution.
BiomX has pivoted from discontinued phage-therapy programs to defense, security and critical-infrastructure technologies through acquisitions of Israeli subsidiaries Zorronet and Dr. Frucht Systems. Auditors have raised a going-concern doubt, the company reported a stockholders’ deficit of $(1,302,000), and it is operating under an NYSE American compliance plan through September 25, 2027 after receiving a listing-deficiency notice.
PFI Genomics, Inc. (PHGE) files a prospectus supplement to offer up to $5,061,000 of Common Stock under its At-the-Market sales agreement with H.C. Wainwright & Co.
The supplement updates the available aggregate offering price under the company’s Form S-3 shelf and states the company has sold approximately $1,376,214 of Common Stock under the agreement to date. It cites an aggregate market value of non-affiliate shares of $19,250,906 based on 10,462,449 non-affiliate shares at $1.84 per share as of April 17, 2026. The filing states there were 11,797,449 shares outstanding as of June 16, 2026 and reports a last reported sale price of $0.555 per share on June 15, 2026.
BiomX Inc. is registering 5,310,933 shares of common stock for resale by existing security holders. The shares consist of 1,650,000 shares issuable upon conversion of Series Y preferred stock, 3,399,000 shares issuable upon exercise of warrants, and up to 261,933 dividend shares.
The company will not receive any proceeds from resale of these shares, but may receive cash if the warrants are exercised, which it plans to use for general corporate purposes. As of February 3, 2026, 1,593,516 shares of common stock were issued and outstanding, and the filing warns that issuing the registered shares could cause substantial dilution and pressure on the stock price.
The preferred stock carries a 15% annual dividend (24% upon certain triggering events), sits senior to other company stock in liquidation, and is subject to ownership and stock exchange limits on how many common shares may be issued before stockholder approval is obtained.